Hereditary pheochromocytoma-paraganglioma
MONDO:0017366Neoplasm predisposition characterized by an increased risk of paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla).
Also known as: familial pheochromocytoma-paraganglioma, hereditary paraganglioma-pheochromocytoma syndrome, hereditary pheochromocytoma-paraganglioma, SDHx-related paraganglioma-pheochromocytoma, hereditary paraganglioma-pheochromocytoma
1487 clinical trials for this condition and its sub-types, 6 tagged with Hereditary pheochromocytoma-paraganglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hereditary pheochromocytoma-paraganglioma
-
MAX-related tumor predisposition 0 trials
-
TMEM127-related tumor predisposition 0 trials
-
Experimental kidney cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control Stopped earlyThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC